SDVG Breakfast: Biotech Financing is Not Dead, It’s Just Different

The San Diego Venture Group has invited Domain Associates partner Eckard Webber and Regulas Therapeutics CEO Kleanthis Xanthopoulos to discuss how life sciences financing has changed in recent years. Inquiring minds want to know: How does royalty-based financing work at an early stage company? Should companies submit their IPO filings confidentially under the new provisions of the JOBS Act? Should companies consider an option deal as an alternative to another private round? More information and online registration is here.